US snaps up first supplies of Regeneron’s COVID-19 antibodyHard on the heels of Regeneron moving its COVID-19 antibody cocktail into late-stage testing, the US government has Share XUS snaps up first supplies of Regeneron’s COVID-19 antibodyhttps://pharmaphorum.com/news/us-snaps-up-first-supplies-of-regenerons-covid-19-antibody/
Regeneron begins late-stage trial testing COVID-19 antibody cocktailRegeneron has begun a late-stage clinical trial testing its double “antibody cocktail” as a preventive treatment for COVID-19. Share XRegeneron begins late-stage trial testing COVID-19 antibody cocktailhttps://pharmaphorum.com/news/regeneron-begins-late-stage-trial-testing-covid-19-antibody-cocktail/
IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialHopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results Share XIL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialhttps://pharmaphorum.com/news/il-6-hypothesis-looking-shaky-as-kevzara-fails-covid-19-trial/
Regeneron gets closer to ISA Pharma with new immuno-oncology allianceRegeneron has doubled down in its ongoing collaboration with ISA Pharma, taking a bigger stake in the Dutch Share XRegeneron gets closer to ISA Pharma with new immuno-oncology alliancehttps://pharmaphorum.com/news/regeneron-gets-closer-to-isa-pharma-with-new-immuno-oncology-alliance/
Regeneron begins trials of COVID-19 antibody cocktailRegeneron has said it has begun clinical trials of its antibody cocktail therapy for COVID-19, as pharma companies continue their search Share XRegeneron begins trials of COVID-19 antibody cocktailhttps://pharmaphorum.com/news/regeneron/
Sanofi sheds Regeneron stake, but insists collaboration is unaffectedSanofi and Regeneron’s once close relationship has been become a little more distant over the last couple of Share XSanofi sheds Regeneron stake, but insists collaboration is unaffectedhttps://pharmaphorum.com/news/sanofi-sheds-regeneron-stake-but-insists-collaboration-is-unaffected/
Sanofi and Regeneron eye challenge to Merck & Co in first line lung cancerSanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy Share XSanofi and Regeneron eye challenge to Merck & Co in first line lung cancerhttps://pharmaphorum.com/news/sanofi-and-regeneron-eye-challenge-to-merck-co-in-first-line-lung-cancer/
Jury still out on IL-6 drugs in COVID-19 following preliminary trial resultsThere is a growing body of evidence that already-approved IL-6 could be used as treatments for COVID-19 following newly published clinical Share XJury still out on IL-6 drugs in COVID-19 following preliminary trial resultshttps://pharmaphorum.com/news/jury-still-out-on-il-6-drugs-in-covid-19-following-preliminary-trial-results/
Regeneron’s Ebola drug heading for October verdict from FDAThe FDA has kicked off a six-month priority review of REGN-EB3, Regeneron’s three-drug therapy for Ebola virus infection, Share XRegeneron’s Ebola drug heading for October verdict from FDAhttps://pharmaphorum.com/news/regenerons-ebola-drug-heading-for-october-verdict-from-fda/
